Rallybio's S-4 Lays Bare the Terms of Its Reverse Merger with Avenzo: Existing Holders Face 97% Dilution Alongside a $215M Concurrent Financing

summarizeSummary

Rallybio's S-4 details its reverse merger with Avenzo Therapeutics, which will leave existing Rallybio stockholders with only 2.8% of the combined company. A $215M concurrent financing and a planned distribution of Rallybio's net cash to pre-close holders are key features.

check_boxKey Events · M&A and Partnerships · RLYB

• Massive Dilution for Existing Holders

  Post-merger, pre-merger Rallybio equityholders will own approximately 2.8% of the combined company, while Avenzo equityholders (excluding Concurrent Financing investors) will own 56.6% and Concurrent Financing investors will own 40.6%.

• $215M Concurrent Financing

  Avenzo has secured a $215.0 million private placement from certain investors, which will close immediately before the merger and further dilute existing Rallybio stockholders.

• Cash Distribution to Rallybio Stockholders

  Rallybio intends to distribute substantially all of its net cash (estimated at $83.2 million as of June 30, 2026) to pre-closing stockholders via Parent Distributions, with up to $50 million declared before the stockholder vote.

• Contingent Value Rights Issued

  Rallybio stockholders will receive one CVR per share, entitling them to proceeds from any future sale of Rallybio's legacy assets and certain payments from Recursion, with a CVR term ending December 31, 2031.

auto_awesomeAnalysis · RLYB · Life Sciences

The S-4 registration statement from Rallybio spells out the definitive terms of its reverse merger with Avenzo Therapeutics. When the dust settles, existing Rallybio stockholders will hold a mere 2.8% of the combined company—a near-total wipeout of their equity stake. The deal is structured as a reverse recapitalization, with Avenzo as the accounting acquirer. Adding to the dilution, a concurrent $215 million financing by Avenzo investors will close immediately before the merger. To partially offset the impact, Rallybio plans to distribute substantially all of its net cash—estimated at $83.2 million as of June 30, 2026—to pre-closing stockholders through one or more Parent Distributions, with up to $50 million declared before the stockholder vote. Stockholders will also receive contingent value rights (CVRs) that entitle them to proceeds from any future sale of Rallybio's legacy assets and certain payments from Recursion. The merger requires stockholder approval of several proposals, including a reverse stock split at a ratio between 1-for-2 and 1-for-9, an increase in authorized shares to 500 million, and the issuance of shares to Avenzo securityholders. Once complete, the combined company will be renamed Avenzo Therapeutics and trade under the symbol 'AVZO'. Closing is expected in Q4 2026. This filing follows the June 1, 2026 announcement of the definitive agreement and provides the granular financial and governance details that will shape the vote.